first-section.png

WHAT WE DO.

third_section.png

PHARMACEUTICALS

We provide our clients with confidence
and assurance that their products will get
to market through provison of QC batch
release testing and regulatory projects.

learn-more2.png
biopharmaceuticals.jpg

BIOPHARMACEUTICALS

Broughton Laboratories is excited to announce the expansion
of its services into the BioPharma Industry in 2017.

learn-more3.png
fifth-section.png

NICOTINE CONTAINING
PRODUCTS

Supporting clients in both the e-cigarette/e-liquid consumer market (EU TPD and US PMTA) and medicinal product development.

learn-fifth.png
animal-health.jpg

ANIMAL HEALTH

We are a MHRA and FDA-inspected facility specialising
in analytical services for Animal Health products.
From product development through to commercial QC
batch release testing, we have the expertise in delivering
tremendous value to our clients.

learn-more.png
lab-image.jpg

STABILITY

From storage only to fully managed storage and analytical studies, our flexible approach means our clients can take advantage of the full range of services or select areas of expertise as required.

footer2_banner.png

BROUGHTON LABS Blog

Building for the Future

Broughton Laboratories is pleased to announce the appointment of Linda McCausland as Operations Director for the Pharma Services sector. Linda brings a wealth of experience having previously held the position of Director of Analytical Services at Almac and will take on the responsibility of routine/development analytical services and stability storage. 

All (computerised) systems Go!

Broughton Laboratories is committed to remaining at the forefront when it comes to computerised systems and are currently running the following projects to keep up to date with current regulatory and client expectations:

Next Generation Nicotine Delivery 2016 – What a difference a year makes

It was the same conference last year where many in the vaping industry realised that changes were coming with regards to the regulations. One year on and there has undoubtedly been a huge shift in attitudes and the realisation that the TPD has not been as restrictive for the industry as first feared. The 2016 event provided a valuable insight into the positive and negative impact of regulations along with how the industry is likely to evolve.

What has been learned from the Tobacco Products Directive (TPD)?

With only a couple of weeks left until the 19th of November we have helped many clients ensure their products are TPD compliant and we are still seeing a significant number of enquiries from both new and existing clients.

The MHRA have remained firm with regards to the deadlines but we have seen many companies look to utilise the sell through period to minimise disruption to their supply chain. Within the guidance for retailers (here) non-compliant stock (manufactured before the 19th of November 2016) may still be sold up until the 19th of May 2017, providing a notification for the non-compliant product is made. The most recent guidance from the MHRA states: